

<b>INFORMATION DISCLOSURE STATEMENT</b> <b>37 C.F.R. § 1.97(b)</b>		ATTORNEY DOCKET NO. <b>70075.0009USWO</b>	
		U.S. APPLICATION SERIAL NO. <b>10/567,407</b>	CONFIRMATION NO. <b>9466</b>
		FILING DATE <b>Not Assigned</b>	
INVENTOR(S) <b>Arthur M. DEBOECK et al.</b>		EXAMINER <b>Not Assigned</b>	
		GROUP ART UNIT <b>N/A</b>	
TITLE OF APPLICATION <b>SINGLE UNIT PHARMACEUTICAL COMPOSITION COMPRISING A MIXTURE OF A FIBRATE AND AN HOMOCYSTEINE REDUCING AGENT</b>			

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. At least some of the references were recently cited in an International Preliminary Report on Patentability mailed April 5, 2006.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided. Enclosed for the Examiner's information is a copy of the International Preliminary Report on Patentability.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached

Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,  
MERCHANT & GOULD, P.C.



William E. Beaumont  
Registration No. 30,996

November 13, 2006

Date

P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
Telephone No. (202) 326-0300  
Facsimile No. (202) 326-0778

**23552**

Patent & Trademark Office

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>INFORMATION DISCLOSURE STATEMENT (PTO 1449)</b>		ATTORNEY DOCKET NO. <b>70075.0009USWO</b>	
		U.S. APPLICATION SERIAL NO. <b>10/567,407</b>	CONFIRMATION NO. <b>9466</b>
		FILING DATE <b>Not Assigned</b>	
INVENTOR(S) <b>Arthur M. DEBOECK et al.</b>		EXAMINER <b>Not Assigned</b>	GROUP ART UNIT <b>N/A</b>
TITLE OF APPLICATION <b>SINGLE UNIT PHARMACEUTICAL COMPOSITION COMPRISING A MIXTURE OF A FIBRATE AND AN HOMOCYSTEINE REDUCING AGENT</b>			

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A	6,465,013	08/15/2002	DeBernardi			

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B	WO 01/56609 A	08/09/2001	WIPO				
	C	DE 199 10 682 A	09/21/2000	GERMANY				
	D	WO 03/013501 A		WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
E	DIERKES, Jutta et al., "Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate," ATHEROSCLEROSIS, vol. 158, no. 1, September 2001 (2001-09), pages 161-164, XP002288439 ISSN: 0021-9150
F	International Preliminary Report on Patentability dated April 5, 2005
G	
H	
I	
J	
K	
L	
M	
N	
O	
P	

EXAMINER	DATE CONSIDERED
<small>EXAMINER: Initial if the reference is considered, whether or not the citation is in conformance with MPEP 609. Draw a line through the citation if it is not in conformance and it is not considered. Include a copy of this form with the next communication to the Applicant.</small>	